Alessio Amatu

Dr. Alessio Amatu

Grande Ospedale Metropolitano Niguarda
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 June 2015 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
Giulia SiravegnaGiulia Siravegna
Giulia Siravegna
BMBenedetta Mussolin
Benedetta Mussolin
MBMichela Buscarino
Michela Buscarino
GCGiorgio Corti
Giorgio Corti
ACAndrea Cassingena
Andrea Cassingena
ABAlberto Bardelli
Alberto Bardelli

1 June 2013 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ABAlberto Bardelli
Alberto Bardelli
Simona CorsoSimona Corso
Simona Corso
ABAndrea Bertotti
Andrea Bertotti
SHSebastijan Hobor
Sebastijan Hobor
EVEmanuele Valtorta
Emanuele Valtorta
SSSalvatore Siena
Salvatore Siena
EGF receptor (EGFR)-targeted monoclonal antibodies are effective in a subset of metastatic colorectal cancers. Inevitably, all patients develop resistance, which occurs through emergence of KRAS mutations in approximately 50% of the cases. We show that amplification of the MET proto-oncogene is associated with acquired resistance in tumors that do not develop KRAS mutations during anti-EGFR therapy. Amplification of the MET locus was present in circulating tumor DNA before relapse was clinically evident. Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro and in vivo. Notably, in patient-derived colorectal cancer xenografts, MET amplification correlated with resistance to EGFR blockade, which could be overcome by MET kinase inhibitors. These results highlight the role of MET in mediating primary and secondary resistance to anti-EGFR therapies in colorectal cancer and encourage the use of MET inhibitors in patients displaying resistance as a result of MET amplification. Significance: Amplification of the MET proto-oncogene is responsible for de novo and acquired resistance to anti-EGFR therapy in a subset of colorectal cancers. As multiple anti-MET therapeutic strategies are available, these findings offer immediate novel opportunities to design clinical studies. Cancer Discov; 3(6); 658–73. ©2013 AACR. This article is highlighted in the In This Issue feature, p. 591

1 January 2016 in ESMO Open
Verified
Journal Article
Open access
PDF file
AAAlessio Amatu
Alessio Amatu
Andrea Sartore-BianchiAndrea Sartore-Bianchi
Andrea Sartore-Bianchi
SSSalvatore Siena
Salvatore Siena
The tropomyosin receptor kinase (Trk) receptor family comprises 3 transmembrane proteins referred to as Trk A, B and C (TrkA, TrkB and TrkC) receptors that are encoded by the NTRK1, NTRK2 and NTRK3 genes, respectively. These receptor tyrosine kinases are expressed in human neuronal tissue and play an essential role in the physiology of development and function of the nervous system through activation by neurotrophins. Gene fusions involving NTRK genes lead to transcription of chimeric Trk proteins with constitutively activated or overexpressed kinase function conferring oncogenic potential. These genetic abnormalities have recently emerged as targets for cancer therapy, because novel compounds have been developed that are selective inhibitors of the constitutively active rearranged proteins. Developments in this field are being aided by next generation sequencing methods as tools for unbiased gene fusions discovery. In this article, we review the role of NTRK gene fusions across several tumour histologies, and the promises and challenges of targeting such genetic alterations for cancer therapy.

20 December 2019 in Science
Verified
Journal Article
Closed access
PDF file
Mariangela RussoMariangela Russo
Mariangela Russo
Giovanni CrisafulliGiovanni Crisafulli
Giovanni Crisafulli
ASAlberto Sogari
Alberto Sogari
NRNicole M. Reilly
Nicole M. Reilly
SASabrina Arena
Sabrina Arena
ABAlberto Bardelli
Alberto Bardelli
A cross-kingdom tale of drug resistance: Physicians who treat bacterial infections and those who treat cancer often face a common challenge: the development of drug resistance. It is well known that when bacteria are exposed to antibiotics, they temporarily increase their mutation rate, thus increasing the chance that a descendant antibiotic-resistant cell will arise. Russo et al. now provide evidence that cancer cells exploit a similar mechanism to ensure their survival after drug exposure (see the Perspective by Gerlinger). They found that human colorectal cancer cells treated with certain targeted therapies display a transient up-regulation of errorprone DNA polymerases and a reduction in their ability to repair DNA damage. Thus, like bacteria, cancer cells can adapt to therapeutic pressure by enhancing their mutability. Science , this issue p. 1473 ; see also p. 1458

1 August 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
Andrea Sartore-BianchiAndrea Sartore-Bianchi
Andrea Sartore-Bianchi
FPFilippo Pietrantonio
Filippo Pietrantonio
SLSara Lonardi
Sara Lonardi
BMBenedetta Mussolin
Benedetta Mussolin
FRFrancesco Rua
Francesco Rua
ABAlberto Bardelli
Alberto Bardelli
Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of resistance mutations restricts their efficacy. We previously showed that RAS, BRAF and EGFR mutant alleles, which appear in circulating tumor DNA (ctDNA) during EGFR blockade, decline upon therapy withdrawal. We hypothesized that monitoring resistance mutations in blood could rationally guide subsequent therapy with anti-EGFR antibodies. We report here the results of CHRONOS, an open-label, single-arm phase 2 clinical trial exploiting blood-based identification of RAS/BRAF/EGFR mutations levels to tailor a chemotherapy-free anti-EGFR rechallenge with panitumumab (ClinicalTrials.gov: NCT03227926; EudraCT 2016-002597-12). The primary endpoint was objective response rate. Secondary endpoints were progression-free survival, overall survival, safety and tolerability of this strategy. In CHRONOS, patients with tissue-RAS WT tumors after a previous treatment with anti-EGFR-based regimens underwent an interventional ctDNA-based screening. Of 52 patients, 16 (31%) carried at least one mutation conferring resistance to anti-EGFR therapy and were excluded. The primary endpoint of the trial was met; and, of 27 enrolled patients, eight (30%) achieved partial response and 17 (63%) disease control, including two unconfirmed responses. These clinical results favorably compare with standard third-line treatments and show that interventional liquid biopsies can be effectively and safely exploited in a timely manner to guide anti-EGFR rechallenge therapy with panitumumab in patients with mCRC. Further larger and randomized trials are warranted to formally compare panitumumab rechallenge with standard-of-care therapies in this patient setting.